Elos Medtech’s dividend policy stipulates that the dividend is to be based on the Group’s earnings performance, while taking into account its future development potential and financial position. The board's assessment is that any surplus funds in the coming years will need to be reinvested into the business, to cover the company's investment needs.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Privacy Policy